From The Australian:
Imagine if universities had to compete with each other to get research work from businesses armed with their own government research grants? Stephen Tomisich, head of Melbourne-based medical technology company Trajan Scientific and Medical...
Read the full article at The Australian website: Research lags in business ventures
Stephen Tomisich, Director and Chief Executive Officer, Trajan Scientific and Medical
Trajan Scientific and Medical’s hemaPEN® microsampling technology has been developed with extensive consultation and evaluation by leading analytical laboratories, clinicians and healthcare professionals.
This month, Trajan presents an exclusive interview with researcher Dr Michele Protti of Pharmaco-Toxicological Analysis, Bologna, Italy, on the future of microsampling and the critical role hemaPEN can play when used in therapeutic drug monitoring for optimal therapy personalization.
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.